Cargando…
Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial
BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, phase III trial comparing synchronous to sequential...
Autores principales: | Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert, Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet, Poole, Christopher J., Rea, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Scientific Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005671/ https://www.ncbi.nlm.nih.gov/pubmed/31785830 http://dx.doi.org/10.1016/j.radonc.2019.10.014 |
Ejemplares similares
-
Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity
por: Fernando, I.N., et al.
Publicado: (2023) -
NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
por: Earl, H M, et al.
Publicado: (2008) -
To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023) -
“From chemo to chemo”—the temporal paradox of chemotherapy
por: Moskalewicz, Marcin, et al.
Publicado: (2021) -
Genetic determinants for chemo- and radiotherapy resistance in bladder cancer
por: Mari, Andrea, et al.
Publicado: (2017)